Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECLIPSE 2
NCT07128550Phase 3Active, not recruiting
- Sponsor
- Vir Biotechnology
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Conjugated siRNA, Monoclonal Antibodies, Chemically Modified siRNA
- Countries
- 7
01
Overview
A Phase 3 trial of tobevibart, elebsiran in hepatitis D virus infection, sponsored by Vir Biotechnology. Started Jul 2025; status: active, not recruiting.
02
Drugs
tobevibartelebsiran
03
Conditions
hepatitis D virus infection
Beyond the preview
Go deeper on NCT07128550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07128550.